Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)

Next Previous
Search
Trial Profile

A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vidutolimod (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Cytos Biotechnology

    • Most Recent Events

    • 14 Apr 2014 Results of this trial will be presented at the American Thoracic Society meeting, according to a Cytos Biotechnology media release.
    • 14 Apr 2014 Status changed from active, no longer recruiting to discontinued, as reported by a Cytos Biotechnology media release.
    • 14 Apr 2014 Primary endpoint 'Significant reduction in Asthma-Control-Questionnaire score with CYT 003 vs placebo at week 12' has not been met, as reported by a Cytos Biotechnology media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top